ArticlePLOS global public health2022
Modelling COVID-19 vaccine breakthrough infections in highly vaccinated Israel-The effects of waning immunity and third vaccination dose.
Article in PLOS global public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review.Systematic reviews · 2024Pooled it
- Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- Evaluating the effectiveness of vaccination campaigns: Insights from unvaccinated mortality data.Infectious Disease Modelling · 2025Article
- Quantifying indirect and direct vaccination effects arising in the SIR model.Journal of the Royal Society, Interface · 2024Article
- Assessing the dynamics and impact of COVID-19 vaccination on disease spread: A data-driven approach.Infectious Disease Modelling · 2024Article
- Impact of Long-COVID in children: a large cohort study.Child and adolescent psychiatry and mental health · 2024Article
- Incidence and risk factors of omicron variant SARS-CoV-2 breakthrough infection among vaccinated and boosted individuals.medRxiv : the preprint server for health sciences · 2024Article
- Covid19Vaxplorer: A free, online, user-friendly COVID-19 vaccine allocation comparison tool.PLOS global public health · 2024Article
- Article
- COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign.Cureus · 2024Review
- Covid19Vaxplorer: a free, online, user-friendly COVID-19 Vaccine Allocation Comparison Tool.medRxiv : the preprint server for health sciences · 2023Article
- Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk.Nature communications · 2023Article
- Improvement of the software for modeling the dynamics of epidemics and developing a user-friendly interface.Infectious Disease Modelling · 2023Article
- Risk averse reproduction numbers improve resurgence detection.PLoS computational biology · 2023Article
- Resolving the enigma of Iquitos and Manaus: A modeling analysis of multiple COVID-19 epidemic waves in two Amazonian cities.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- The impact of COVID-19 vaccination campaign in Hong Kong SAR China and Singapore.Infectious Disease Modelling · 2023Article
- Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination.Journal of theoretical biology · 2023Article
- Article
- An Enhanced SEIR Model for Prediction of COVID-19 with Vaccination Effect.Life (Basel, Switzerland) · 2022Article
- Assessing Vaccination Prioritization Strategies for COVID-19 in South Africa Based on Age-Specific Compartment Model.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In August 2021, a major wave of the SARS-CoV-2 Delta variant erupted in the highly vaccinated population of Israel. The transmission advantage of the Delta variant enabled it to replace the Alpha variant in approximately two months. The outbreak led to an unexpectedly large proportion of breakthrough infections (BTI)-a phenomenon that received worldwide attention. Most of the Israeli population, especially those aged 60+, received their second dose of the vaccination four months before the invasion of the Delta variant. Hence, either the vaccine induced immunity dropped significantly or the Delta variant possesses immunity escaping abilities, or both. In this work, we model data obtained from the Israeli Ministry of Health, to help understand the epidemiological factors involved in the outbreak. We propose a mathematical model that captures a multitude of factors, including age structure, the time varying vaccine efficacy, time varying transmission rate, BTIs, reduced susceptibility and infectivity of vaccinated individuals, protection duration of the vaccine induced immunity, and the vaccine distribution. We fitted our model to COVID-19 cases among the vaccinated and unvaccinated, for <60 and 60+ age groups, and quantified the transmission rate, the vaccine efficacy over time and the impact of the third dose booster vaccine. The peak transmission rate of the Delta variant was found to be 2.14 times higher than that of the Alpha variant. The two-dose vaccine efficacy against infection dropped significantly from >90% to ~40% over 6 months. We further performed model simulations and quantified counterfactual scenarios examining what would happen if the booster had not been rolled out. We estimated that approximately 4.03 million infective cases (95%CI 3.19, 4.86) were prevented by vaccination overall, and 1.22 million infective cases (95%CI 0.89, 1.62) averted by the booster.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.